TriSalus Life Sciences (TLSI) Revenue (2022 - 2026)

TriSalus Life Sciences has reported Revenue for 5 years, with the latest figure at $11.4 million in Q2 2026.

• On a quarterly basis, Revenue rose 1.73% year-over-year to $11.4 million in Q2 2026; TTM through Jun 2026 was $45.1 million, a 25.25% increase from a year earlier, with the FY2025 full-year figure at $45.2 million, up 53.41% from the prior year.
• Revenue was $11.4 million for Q2 2026 at TriSalus Life Sciences, up from $8.9 million in the prior quarter.
• The five-year high for Revenue was $13.2 million in Q4 2025, with the low at $3.0 million in Q1 2023.
• Average Revenue over 5 years is $7.5 million, with a median of $7.4 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2026: Revenue soared 116.39% in 2024, then retreated 2.92% in 2026.
• Over 5 years, Revenue stood at $3.2 million in 2022, then soared by 77.34% to $5.7 million in 2023, then jumped by 44.4% to $8.3 million in 2024, then soared by 59.85% to $13.2 million in 2025, then dropped by 13.62% to $11.4 million in 2026.
• The last three Revenue figures came in at $11.4 million (Q2 2026), $8.9 million (Q1 2026), and $13.2 million (Q4 2025), per Business Quant data.